世界科学技术-中医药现代化
世界科學技術-中醫藥現代化
세계과학기술-중의약현대화
World Science and Technology-Modernization of Traditional Chinese Medicine
2015年
8期
1664-1668
,共5页
王志光%林丽珠%王三虎%范先基%邢晓娟%张定进%杨子玉
王誌光%林麗珠%王三虎%範先基%邢曉娟%張定進%楊子玉
왕지광%림려주%왕삼호%범선기%형효연%장정진%양자옥
通补三升汤%肺鳞癌%近期疗效%无进展生存期
通補三升湯%肺鱗癌%近期療效%無進展生存期
통보삼승탕%폐린암%근기료효%무진전생존기
Tong-Bu San-ShengDecoction%lung squamous carcinoma%short-term outcome%progression-free survival
目的：研究中药通补三升汤对晚期肺鳞癌化疗患者毒副反应及肿瘤无进展生存期（Progression-free survival，PFS）的干预作用。方法：选取符合标准的83例晚期肺鳞癌患者，按患者意愿分为治疗组42例及对照组41例，对照组采用GP方案（吉西他滨+顺铂）化疗，治疗组接受化疗的同时服用中药通补三升汤。评价两组患者化疗期间毒副反应及近期疗效，记录患者PFS。结果：两组患者治疗后粒细胞水平降低无差异（P=0.115），两组患者的近期疗效亦无差异（P=0.081）；治疗组发生恶心呕吐及血小板水平降低的几率低于对照组（P=0.037、P=0.040），治疗组患者的PFS较对照组患者延长（4.31±0.24 VS 3.78±0.16月，P=0.043）。结论：中药通补三升汤不能改善肺鳞癌患者化疗期间的粒细胞水平降低程度，也不能提高近期有效率（Response Rate RR），但能延长PFS，并对化疗期间的恶心呕吐反应及血小板水平降低有改善作用。
目的：研究中藥通補三升湯對晚期肺鱗癌化療患者毒副反應及腫瘤無進展生存期（Progression-free survival，PFS）的榦預作用。方法：選取符閤標準的83例晚期肺鱗癌患者，按患者意願分為治療組42例及對照組41例，對照組採用GP方案（吉西他濱+順鉑）化療，治療組接受化療的同時服用中藥通補三升湯。評價兩組患者化療期間毒副反應及近期療效，記錄患者PFS。結果：兩組患者治療後粒細胞水平降低無差異（P=0.115），兩組患者的近期療效亦無差異（P=0.081）；治療組髮生噁心嘔吐及血小闆水平降低的幾率低于對照組（P=0.037、P=0.040），治療組患者的PFS較對照組患者延長（4.31±0.24 VS 3.78±0.16月，P=0.043）。結論：中藥通補三升湯不能改善肺鱗癌患者化療期間的粒細胞水平降低程度，也不能提高近期有效率（Response Rate RR），但能延長PFS，併對化療期間的噁心嘔吐反應及血小闆水平降低有改善作用。
목적：연구중약통보삼승탕대만기폐린암화료환자독부반응급종류무진전생존기（Progression-free survival，PFS）적간예작용。방법：선취부합표준적83례만기폐린암환자，안환자의원분위치료조42례급대조조41례，대조조채용GP방안（길서타빈+순박）화료，치료조접수화료적동시복용중약통보삼승탕。평개량조환자화료기간독부반응급근기료효，기록환자PFS。결과：량조환자치료후립세포수평강저무차이（P=0.115），량조환자적근기료효역무차이（P=0.081）；치료조발생악심구토급혈소판수평강저적궤솔저우대조조（P=0.037、P=0.040），치료조환자적PFS교대조조환자연장（4.31±0.24 VS 3.78±0.16월，P=0.043）。결론：중약통보삼승탕불능개선폐린암환자화료기간적립세포수평강저정도，야불능제고근기유효솔（Response Rate RR），단능연장PFS，병대화료기간적악심구토반응급혈소판수평강저유개선작용。
This study was aimed to investigate the efficacy ofTong-Bu San-Sheng(TBSS) Decoction to reduce the toxicity and side effects of chemotherapy, as well as prolong progression-free survival (PFS) for advanced lung squamous carcinoma patients who received chemotherapy. A total of 83 lung squamous carcinoma cases were divided into two groups by patients’ wishes. The control group contained 41 cases were treated by the chemotherapy of gemcitabine plus cisplatin (GP). The trial group contained 42 cases were treated by chemotherapy plus Chinese herbal medicine TBSS decoction. The toxicity and side effects of chemotherapy, as well as short-term outcome were evaluated. PFS of patient was recorded. The results showed that there were no differences on granulocytopenia (P = 0.115) or short-term outcome (P = 0.081) for patients of both groups after chemotherapy. The percentages of nausea, vomiting and thrombocytopenia in the trial group were lower than that in the control group (P = 0.037,P = 0.040). The PFS of patients in the trail group were prolonged compared to patients in the control group (4.31 ± 0.24 VS 3.78 ± 0.16 month;P = 0.043). It was concluded that Chinese herbal medicine TBSS decoction cannot reduce granulocytopenia caused by chemotherapy, or improve the tumor response rate (RR) of short-term outcome. However, it can prolong PFS, relieve nausea, vomiting and thrombocytopenia during chemotherapy.
